Eidos Therapeutics � acoramidis (AG10)

Eidos Therapeutics, founded by Isabella Graef, MD and Mamoun Alhamadsheh, PharmD, PhD. Transthyretin (TTR) amyloidosis (ATTR) is a rare, often underdiagnosed, and life-threatening disease with limited treatment options that can devastate the heart and nervous system. The Eidos Therapeutics mission is to address the significant unmet needs of patients with this disease through the discovery and development of novel therapeutics. In pre-clinical studies, acoramidis (AG10) was shown to bind TTR tetramers at the same central locations at which the T119M variant forms stabilizing bonds. This unique binding mode is thought to underlie the potent stabilization of TTR by acoramidis (AG10).